Janssen: latest news - GoINPHARMA
Monday, 10 December 2018 - 3:45

Janssen

Janssen obtains FDA approval for Darzalex (multiple myeloma)

Janssen, part of Johnson & Johnson group, has announced it has obtained the FDA approval for Darzalex in combination with Takeda’s Velcade and prednisone as a first-line therapy against multiple myeloma. The approval reflects positive results obtained in the Phase-III…

Janssen invests in Ireland

US-based Janssen – part of Johnson and Johnson group – has announced in a press release a €300m plan to expand its Ringaskiddy plant (Cork, Ireland), which will generate at least 200 new jobs when at full capacity (October 2019)….

Xarelto significantly reduces major cardiovascular events

Results from the Phase III COMPASS study found that Xarelto (rivaroxaban) 2.5 mg twice daily, plus aspirin 100 mg once daily, significantly reduced the risk of major cardiovascular events: the rate of CV death, heart attack or stroke decreased by…

Genmab in talks with Janssen

Denmark-based group Genmab apparently attracted interest from Janssen Pharmaceuticals, which could be targeting an acquisition. The two partners developed the anti-cancer Darzalex, a blockbuster worth $8bn – $9bn. If Janssen manages to acquire Genmab, it will avoid the $815m coupon…

WHO: Janssen completes application for Ebola vaccine

Janssen Vaccines & Prevention B.V., part of the Johnson & Johnson group, has completed its application to the World Health Organization (WHO) for an Emergency Use Assessment and Listing (EUAL) for its investigational preventive Ebola vaccine. EUAL is a procedure…